Drug Patents owned by Sanofi Aventis Us

1. List of Aubagio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6794410 SANOFI AVENTIS US Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis
Sep, 2026

(3 years from now)

US6794410

(Pediatric)

SANOFI AVENTIS US Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis
Mar, 2027

(4 years from now)

US8802735 SANOFI AVENTIS US (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
Sep, 2030

(7 years from now)

US8802735

(Pediatric)

SANOFI AVENTIS US (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
Mar, 2031

(8 years from now)

US9186346 SANOFI AVENTIS US Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
Feb, 2034

(10 years from now)

US9186346

(Pediatric)

SANOFI AVENTIS US Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
Aug, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
M Apr 30, 2024
Pediatric Exclusivity (PED) Oct 30, 2024

Drugs and Companies using TERIFLUNOMIDE ingredient

Market Authorisation Date: 12 September, 2012

Treatment: Treatment of patients with relapsing forms of multiple sclerosis; Treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction by limiting the rosuvastatin dose to no more than 10mg and/or administering about half the normal dose

Dosage: TABLET;ORAL

How can I launch a generic of AUBAGIO before it's patent expiration?
More Information on Dosage

AUBAGIO family patents

17

United States

6

European Union

4

China

3

Israel

3

Peru

2

Hong Kong

2

Australia

2

Chile

2

Ukraine

2

Uruguay

2

Spain

2

Cyprus

2

Slovenia

2

Argentina

2

Portugal

2

Russia

2

New Zealand

2

Honduras

2

Canada

2

Taiwan, Province of China

2

Denmark

2

Costa Rica

1

Austria

1

Morocco

1

RS

1

Korea, Republic of

1

Brazil

1

Poland

1

Lithuania

1

Malaysia

1

Luxembourg

1

Guatemala

1

Dominican Republic

1

Jordan

1

Germany

1

Mexico

1

Japan

1

Tunisia

1

Hungary

1

Ecuador

1

United Kingdom

1

Colombia

1

Belgium

1

Croatia

1

ME

1

Panama

1

Nicaragua

2. List of Jevtana Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7241907 SANOFI AVENTIS US Acetone solvate of dimethoxy docetaxel and its process of preparation
Dec, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7241907

(Pediatric)

SANOFI AVENTIS US Acetone solvate of dimethoxy docetaxel and its process of preparation
Jun, 2026

(3 years from now)

US10583110 SANOFI AVENTIS US Antitumoral use of cabazitaxel
Oct, 2030

(7 years from now)

US8927592 SANOFI AVENTIS US Antitumoral use of cabazitaxel
Oct, 2030

(7 years from now)

US10716777 SANOFI AVENTIS US Antitumoral use of cabazitaxel
Oct, 2030

(7 years from now)

US8927592

(Pediatric)

SANOFI AVENTIS US Antitumoral use of cabazitaxel
Apr, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
M Dec 18, 2023

Drugs and Companies using CABAZITAXEL ingredient

Market Authorisation Date: 17 June, 2010

Treatment: Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering as a 3 week cycle cabazitaxel after 5 mg dexchlorpheniramine, 8 mg dexamethasone, and an h2-agonist; Increasing survival in mcrpc patients previously treated with docetaxel by administering cabazitaxel in combination with prednisone or prednisolone after a premedication regimen that includes an antihistamine, a corticosteroid, and an h2-antagonist; Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering 20 to 25 mg/m2 cabazitaxel after a premedication regimen that includes an h2-antagonist

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of JEVTANA KIT before it's patent expiration?
More Information on Dosage

JEVTANA KIT family patents

16

United States

6

Australia

5

New Zealand

4

China

3

Japan

3

Canada

3

Taiwan, Province of China

2

Morocco

2

Korea, Republic of

2

Brazil

2

Poland

2

Malaysia

2

Ukraine

2

Spain

2

Israel

2

Mexico

2

Tunisia

2

Argentina

2

South Africa

2

Portugal

2

Peru

2

ME

2

Norway

2

France

2

Denmark

2

Costa Rica

2

European Union

1

Hong Kong

1

RS

1

Chile

1

Guatemala

1

Luxembourg

1

Dominican Republic

1

Yugoslavia

1

Uruguay

1

Cyprus

1

Slovenia

1

IB

1

Hungary

1

El Salvador

1

Colombia

1

Singapore

1

Russia

1

EA

1

Croatia

1

Nicaragua

1

Panama

1

Ecuador

3. List of Multaq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9107900 SANOFI AVENTIS US Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality
Apr, 2029

(6 years from now)

US8410167 SANOFI AVENTIS US Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
Apr, 2029

(6 years from now)

US8602215 SANOFI AVENTIS US Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
Jun, 2031

(8 years from now)

Drugs and Companies using DRONEDARONE HYDROCHLORIDE ingredient

Market Authorisation Date: 01 July, 2009

Treatment: Reduction in risk of hospitalization in patients with stable nyha class iii heart failure and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals; Reduction in risk of hospitalization in patients with coronary heart disease and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals; Reduction in risk of hospitalization in patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a day with morning and evening meals; Treatment of patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a day with morning and evening meals; Management of risk of dronedarone/beta-blocker interaction in patients in sinus rythm with a history of paroxysmal or persistent af

Dosage: TABLET;ORAL

How can I launch a generic of MULTAQ before it's patent expiration?
More Information on Dosage

MULTAQ family patents

19

United States

8

European Union

3

France

3

Taiwan, Province of China

2

Morocco

2

Korea, Republic of

2

Brazil

2

Australia

2

Chile

2

Dominican Republic

2

Uruguay

2

Mexico

2

Japan

2

IB

2

Ecuador

2

South Africa

2

Argentina

2

El Salvador

2

Colombia

2

Peru

2

EA

2

China

2

Canada

2

Costa Rica

2

Nicaragua

1

Malaysia

1

Ukraine

1

Tunisia

1

New Zealand

4. List of Oforta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7148207 SANOFI AVENTIS US Oral fludara of high-purity formulation with quick release of active ingredient
Dec, 2022

(a month ago)

Drugs and Companies using FLUDARABINE PHOSPHATE ingredient

Market Authorisation Date: 18 December, 2008

Treatment: Treatment of patients with b-cell chronic lymphocytic leukemia (cll)

Dosage: TABLET;ORAL

More Information on Dosage

OFORTA family patents

2

Germany

2

Japan

2

United States

2

European Union

1

Austria

1

Hong Kong

1

Korea, Republic of

1

Brazil

1

Australia

1

Poland

1

Saudi Arabia

1

Ukraine

1

Yugoslavia

1

Uruguay

1

Jordan

1

Spain

1

Israel

1

Mexico

1

South Africa

1

Argentina

1

Peru

1

Russia

1

Croatia

1

China

1

Norway

1

Canada

1

New Zealand

1

Taiwan, Province of China

1

Denmark

1

Ecuador

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic